Compare SXC & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | LBRX |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | 848 | 27 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 850.5M |
| IPO Year | 2011 | N/A |
| Metric | SXC | LBRX |
|---|---|---|
| Price | $8.09 | $30.71 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 1.4M | 218.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,600,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.30 | N/A |
| 52 Week Low | $5.52 | $13.40 |
| 52 Week High | $9.74 | $33.47 |
| Indicator | SXC | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.26 | 59.24 |
| Support Level | $7.70 | $26.75 |
| Resistance Level | $8.47 | $33.47 |
| Average True Range (ATR) | 0.36 | 1.70 |
| MACD | -0.21 | 0.28 |
| Stochastic Oscillator | 1.50 | 69.52 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.